#1 Clinical Trials Search in Europe

Siponimod Fumaric Acid

This article explores the use of Siponimod Fumaric Acid in clinical trials for the treatment of multiple sclerosis (MS). Siponimod Fumaric Acid is being studied in both pediatric and adult patients with various forms of MS, including secondary progressive MS. The trials aim to evaluate the drug’s efficacy, safety, and its effects on various aspects of the disease, such as relapse rates, brain lesions, and biomarkers associated with MS progression.

Table of Contents

What is Siponimod?

Siponimod fumaric acid, also known by its research code BAF312, is a medication used to treat certain forms of multiple sclerosis (MS)[1]. Multiple sclerosis is a condition where the immune system mistakenly attacks the protective covering of nerve fibers, leading to communication problems between the brain and the rest of the body. This can result in various symptoms and disability.

How Siponimod Works

Siponimod belongs to a class of drugs called sphingosine 1-phosphate (S1P) receptor modulators[1]. It works by binding to specific receptors on immune cells, which helps to keep these cells in the lymph nodes. This action reduces the number of immune cells circulating in the blood and entering the central nervous system, where they could cause damage in MS patients.

Treating Multiple Sclerosis with Siponimod

Siponimod is specifically used to treat active forms of MS, including:

  • Secondary progressive multiple sclerosis (SPMS): This is a stage of MS that follows relapsing-remitting MS, where symptoms steadily worsen over time[2].
  • Active progressive multiple sclerosis: This refers to MS that is showing signs of ongoing disease activity, such as new relapses or changes on MRI scans[2].

The medication aims to slow down the progression of disability in these patients and reduce the frequency of relapses or flare-ups of MS symptoms.

Clinical Studies on Siponimod

Several clinical trials are being conducted to evaluate the effectiveness and safety of siponimod in treating MS:

  • A study comparing siponimod to other MS treatments in children with multiple sclerosis[1].
  • A trial investigating how siponimod affects certain features of MS visible on MRI scans, specifically paramagnetic rim lesions[2]. These are a type of brain lesion associated with ongoing inflammation in MS.
  • Research on how siponimod impacts various biomarkers in the blood and cerebrospinal fluid that indicate MS activity[2].

These studies aim to provide more information about how well siponimod works and its effects on different aspects of MS.

Dosage and Administration

Siponimod is taken orally in the form of film-coated tablets[1][2]. The typical maximum daily dose is 2 mg, but the exact dosage may vary depending on the individual patient and their specific condition. Always follow your doctor’s instructions regarding dosage and administration.

Potential Side Effects

As with all medications, siponimod can cause side effects. Some potential side effects include:

  • Increased risk of infections
  • Changes in heart rate or rhythm
  • Liver problems
  • Vision problems
  • Breathing difficulties

Your healthcare provider will monitor you closely for these and other potential side effects[2].

Who Should Not Take Siponimod?

Siponimod may not be suitable for everyone. You should not take siponimod if you:

  • Have certain heart conditions
  • Have severe liver problems
  • Are pregnant or breastfeeding
  • Have had certain recent vaccinations
  • Have certain genetic variations affecting how your body processes the drug

Always inform your healthcare provider about your full medical history and any other medications you are taking before starting siponimod[2].

Aspect Details
Drug Name Siponimod Fumaric Acid
Administration Oral, film-coated tablet
Conditions Studied Multiple Sclerosis (pediatric and adult), Secondary Progressive MS, Active Progressive MS
Primary Objectives Evaluate efficacy in reducing relapse rates, assess effects on brain lesions, study impact on MS biomarkers
Key Endpoints Annualized relapse rate, number of new/enlarging T2 lesions, changes in neurofilament light chain levels, effects on paramagnetic rim lesions
Safety Assessments Adverse events, laboratory tests, ECG, vital signs, cognitive function
Notable Exclusions Certain heart conditions, severe liver dysfunction, active infections, recent use of specific MS treatments

FAQ

  • What is Siponimod Fumaric Acid? Siponimod Fumaric Acid is a medication being studied for the treatment of multiple sclerosis. It belongs to a class of drugs called receptor modulators and is taken orally as a film-coated tablet.
  • What types of multiple sclerosis are being studied with Siponimod Fumaric Acid? Siponimod Fumaric Acid is being studied in both pediatric and adult patients with various forms of multiple sclerosis, including secondary progressive MS and active progressive MS.
  • What are the main goals of the clinical trials using Siponimod Fumaric Acid? The main goals include evaluating the drug's effectiveness in reducing relapse rates, assessing its impact on brain lesions visible on MRI scans, studying its effects on biomarkers associated with MS progression, and determining its safety and tolerability in patients.
  • How is Siponimod Fumaric Acid administered? Siponimod Fumaric Acid is administered orally as a film-coated tablet. The maximum daily dose in the trials is typically 2 mg, but this may vary depending on the specific study.
  • Are there any specific exclusion criteria for participating in these trials? Yes, there are several exclusion criteria. These include certain heart conditions, severe liver dysfunction, active infections, pregnancy or breastfeeding, and recent use of specific MS treatments. Patients with a history of certain medical conditions or those taking certain medications may also be excluded.

Ongoing Clinical Trials on Siponimod Fumaric Acid

  • Study on the Effects of Siponimod on Imaging and Immune Markers in Patients with Progressive Multiple Sclerosis

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

  • Study on the Effectiveness and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Children with Multiple Sclerosis

    Not recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Croatia Estonia France Germany +7

Glossary

  • Multiple Sclerosis (MS): A chronic disease affecting the central nervous system, where the immune system attacks the protective covering of nerves.
  • Annualized Relapse Rate (ARR): The average number of relapses a patient with MS experiences per year.
  • EDSS (Expanded Disability Status Scale): A method of measuring disability in multiple sclerosis and monitoring changes in the level of disability over time.
  • T2 Lesions: Areas of damage in the brain or spinal cord caused by MS that can be seen on MRI scans.
  • Neurofilament Light Chain (NfL): A protein released into the blood and cerebrospinal fluid when nerve cells are damaged, used as a biomarker in MS.
  • Paramagnetic Rim Lesions: A type of brain lesion associated with chronic active inflammation in MS, visible on specialized MRI scans.
  • Secondary Progressive MS: A phase of MS that follows relapsing-remitting MS, characterized by a steady increase in disability.
  • Biomarker: A measurable indicator of the severity or presence of some disease state, used to evaluate the effectiveness of treatments.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-ofatumumab-and-siponimod-compared-to-fingolimod-in-children-with-multiple-sclerosis/
  2. http://clinicaltrials.eu/trial/study-on-the-effects-of-siponimod-on-imaging-and-immune-markers-in-patients-with-progressive-multiple-sclerosis/